biologic

Oncaspar

pegaspargase

Loss of exclusivityFebruary 2006projected — 12-year biologic exclusivity estimate
CompanyServier Pharmaceuticals LLC

Drug detail

Brand nameOncaspar
Active ingredientpegaspargase
Strength3,750IU/5ML(750IU/ML)
Dosage formInjection
RouteIntravenous, Intramuscular
ModalityBiologic
FDA approvalFebruary 1994
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Oncaspar patent cliff — loss of exclusivity February 2006 | CliffBio